These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27044813)

  • 1. Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy.
    Valiulienė G; Treigytė G; Savickienė J; Matuzevičius D; Alksnė M; Jarašienė-Burinskaja R; Bukelskienė V; Navakauskas D; Navakauskienė R
    Biomed Pharmacother; 2016 Apr; 79():62-70. PubMed ID: 27044813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
    Valiulienė G; Vitkevičienė A; Navakauskienė R
    Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
    Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
    J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
    Savickiene J; Treigyte G; Vistartaite G; Tunaitis V; Magnusson KE; Navakauskiene R
    Differentiation; 2011 Jan; 81(1):57-67. PubMed ID: 20864248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
    He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
    J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
    Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
    Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
    Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
    Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results.
    Coradini D; Pellizzaro C; Scarlata I; Zorzet S; Garrovo C; Abolafio G; Speranza A; Fedeli M; Cantoni S; Sava G; Daidone MG; Perbellini A
    Leukemia; 2006 May; 20(5):785-92. PubMed ID: 16525489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex context relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for all-trans retinoic acid in cancer therapy.
    Garsuault D; Bouyer C; Nguyen E; Kandhari R; Prochazkova-Carlotti M; Chevret E; Forgez P; Ségal-Bendirdjian E
    Mol Oncol; 2020 Jun; 14(6):1310-1326. PubMed ID: 32239597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
    Kosugi H; Ito M; Yamamoto Y; Towatari M; Ito M; Ueda R; Saito H; Naoe T
    Jpn J Cancer Res; 2001 May; 92(5):529-36. PubMed ID: 11376562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.
    Savickiene J; Treigyte G; Jonusiene V; Bruzaite R; Borutinskaite VV; Navakauskiene R
    Mol Cell Biochem; 2012 Jan; 359(1-2):245-61. PubMed ID: 21842375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.
    Martens JH; Brinkman AB; Simmer F; Francoijs KJ; Nebbioso A; Ferrara F; Altucci L; Stunnenberg HG
    Cancer Cell; 2010 Feb; 17(2):173-85. PubMed ID: 20159609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
    Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
    Leiva M; Moretti S; Soilihi H; Pallavicini I; Peres L; Mercurio C; Dal Zuffo R; Minucci S; de Thé H
    Leukemia; 2012 Jul; 26(7):1630-7. PubMed ID: 22333881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
    Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
    Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.